Day: June 5, 2023

BELO HORIZONTE, Brazil, June 05, 2023 (GLOBE NEWSWIRE) — Inter&Co, Inc (Inter), (NASDAQ: INTR | B3: INBR32), the premier Super App which provides financial and digital commerce services to more than 26 million customers, today announced the appointment of Claudia Farkouh Prado to its board of directors. Claudia brings over 25 years of expertise in law, M&A, corporate leadership, value creation, and risk management.  Claudia is currently an independent board member of B3 S.A. – Brasil, Bolsa, Balcão, the main financial exchange in Brazil, where she also serves as a coordinator on its Governance and Nomination Committee, and is a member of its Personnel and Compensation Committee and Sustainability Committee. At leading global law firm Baker McKenzie, Claudia was a member of the board of directors, president of Latin America,...

SHANGHAI, June 05, 2023 (GLOBE NEWSWIRE) — Atour Lifestyle Holdings Limited (“Atour” or the “Company”) (NASDAQ: ATAT), a leading hospitality and lifestyle company in China, today announced the commencement of a proposed registered underwritten offering by entities affiliated with Legend Capital (“Legend Capital”) of American depositary shares (the “ADSs”), each ADS representing three Class A ordinary shares of the Company. Legend Capital proposes to offer an aggregate of 4,800,000 ADSs (the “Secondary Offering”). The underwriters in the Secondary Offering have a 30-day option to purchase up to 720,000 additional ADSs from Legend Capital. The Company will not receive any proceeds from the sale of the ADSs by Legend Capital. BofA Securities, Inc. and CMB International Capital Limited act as the joint bookrunners for the proposed...

CALGARY, Alberta, June 05, 2023 (GLOBE NEWSWIRE) — Cenovus Energy Inc. (TSX: CVE) (NYSE: CVE) has safely restarted approximately 62,000 barrels of oil equivalent per day (BOE/d) of production, from the 85,000 BOE/d impacted in May due to wildfires. Assuming the current wildfire conditions continue, Rainbow Lake operations are expected to return to production within seven to 10 days, which represents approximately 20,000 BOE/d. About 3,000 BOE/d remains offline awaiting power infrastructure to be rebuilt in various remote locations. As staff have been able to access sites, to date no significant damage has been identified. The overall wildfire situation continues to be closely monitored and other assets, including the company’s oil sands operations and Lloydminster complex, have not been impacted. Cenovus is grateful for the efforts...

CALGARY, Alberta , June 05, 2023 (GLOBE NEWSWIRE) — As previously announced, NuVista Energy Ltd.’s (TSX:NVA, “NVA” or “NuVista”) production was temporarily impacted by the wildfires in the Grande Prairie region of Alberta. Specifically, several of our fields were shut in on May 5th as a precautionary measure to ensure the protection of our people, the public, and our assets in the vicinity of the wildfires. As a result of improving conditions, we were able to gradually restart our operations commencing the week of May 22nd. NuVista’s production has now reached a new record of approximately 80,000 Boe/d. Our production guidance for the second quarter of 2023 is approximately 71,000 Boe/d, including the overall impact of the wildfires of approximately 11,000 Boe/d. Over the second half of 2023, we anticipate...

– Compassionate use enables treating physicians in Germany to request access to investigational TransCon PTH (palopegteriparatide) for eligible adult patients with hypoparathyroidism COPENHAGEN, Denmark, June 05, 2023 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has started enrollment for a Compassionate Use Program (CUP) in Germany for TransCon PTH (palopegteriparatide), an investigational prodrug designed to provide sustained release of active parathyroid hormone (PTH 1-34) within the physiological range for 24 hours per day in adult patients with hypoparathyroidism with once-daily administration. The CUP was approved by Germany’s Federal Institute for Drugs & Medical Devices (Bundesinstitut für Arzneimittel & Medizinprodukte, or BfArM). “We are pleased to offer this pre-approval Compassionate...

             NEWS RELEASE – REGULATED INFORMATIONJUNE 5, 2023, 5:30 pm ET/ 23:30 CEST MDxHealth Announces its Extraordinary General Shareholders’ Meeting IRVINE, CA, and HERSTAL, BELGIUM – June 5, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the “Company” or “mdxhealth“), a commercial-stage precision diagnostics company, today invites the holders of securities issued by the Company to its extraordinary general shareholders’ meeting that will be held on Friday, June 30, 2023 at 9:00 a.m., Belgian time. The items on the agenda of the extraordinary general shareholders’ meeting include the issuance of a new share option plan called the “2023 Share Option Plan” and the renewal of the authorization to the board of directors to increase the share capital within the framework of the...

JUPITER-02 Final Overall Survival Analysis in Intent-To-Treat Population Presented at ASCO 2023– Toripalimab plus chemotherapy resulted in a 37% reduction in the risk of death, HR=0.63, versus chemotherapy alone, in nasopharyngeal carcinoma patients – – No treatments are approved for NPC in the US; if approved, toripalimab will address a critical unmet need – REDWOOD CITY, Calif., June 05, 2023 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) announced the final overall survival (OS) results of the JUPITER-02 study presented today at the American Society for Clinical Oncology (ASCO) Annual Meeting. JUPITER-02 is a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab in combination with gemcitabine and cisplatin as a first-line treatment for patients with recurrent or...

SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) — Telesis Bio Inc. (NASDAQ: TBIO), a leader in molecular biology automation solutions for multi-omic and synthetic biology applications, today announced the closing of its private placement of redeemable convertible preferred stock and warrants resulting in initial gross proceeds of $28.0 million to Telesis Bio. The warrants issued in the private placement will provide Telesis Bio with approximately $46.2 million in additional gross proceeds if they are cash exercised. The financing was led by Novalis LifeSciences LLC with participation from Northpond Ventures, BroadOak Capital Partners and M-185 Corporation, an affiliate of the Company’s Chief Executive Officer and Founder, Todd R. Nelson, PhD. The Company also announced the appointment of Paul Meister, a partner at Novalis LifeSciences...